{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:22:12Z","timestamp":1787851332591,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008963","name":"Spanish Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108335","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:49:44Z","timestamp":1784746184000},"page":"108335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4\/6 inhibitors plus endocrine therapy in HR-positive\/HER2-negative metastatic breast cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"M.","family":"Cruellas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4899-6607","authenticated-orcid":false,"given":"A.","family":"Rodriguez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Carit\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-9825","authenticated-orcid":false,"given":"E.","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cejuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8527-3398","authenticated-orcid":false,"given":"L.","family":"Lema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-2182","authenticated-orcid":false,"given":"E.","family":"Garc\u00eda-Torralba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-7463","authenticated-orcid":false,"given":"A.","family":"Roqu\u00e9-Lloveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5921-0246","authenticated-orcid":false,"given":"A.","family":"Fern\u00e1ndez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6988-4519","authenticated-orcid":false,"given":"S.","family":"Servitja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gonz\u00e1lez-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Blaya-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2128-7197","authenticated-orcid":false,"given":"I.","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-4703","authenticated-orcid":false,"given":"I.","family":"Garc\u00eda-Fructuoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Joval-Ramentol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vi\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9023-0275","authenticated-orcid":false,"given":"M.","family":"Rey Aceituno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-8799","authenticated-orcid":false,"given":"M.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-6415","authenticated-orcid":false,"given":"J.","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108335_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102496","article-title":"Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer","volume":"112","author":"Falato","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108335_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108335_bib3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN guidelines(R) insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108335_bib4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/OP.23.00771","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline Q and A","volume":"20","author":"Kurian","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108335_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31427","article-title":"Universal genetic testing for newly diagnosed invasive breast cancer","volume":"7","author":"Rezoug","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108335_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108335_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.annonc.2025.04.012","article-title":"Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations","volume":"36","author":"Turnbull","year":"2025","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108335_bib8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2020.0229","article-title":"Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer","volume":"323","author":"Kurian","year":"2020","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.esmoop.2026.108335_bib9","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.esmoop.2026.108335_bib10","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108335_bib11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108335_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108335_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108335_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108335_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108335_bib16","article-title":"Impact of BRCA mutation on treatment outcomes of endocrine therapy +\/\u2212 CDK4\/6 inhibitors in hormone receptor-positive\/human epidermal growth factor receptor-2-negative breast cancer: a systematic review and meta-analysis","volume":"9","author":"Azim","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108335_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104544","article-title":"Impact of germline BRCA1\/2 status on outcomes for patients with HR+\/HER2\u2212 metastatic breast cancer treated with CDK4\/6 inhibitors: a systematic review and meta-analysis","volume":"83","author":"Bottosso","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2026.108335_bib18","article-title":"Cyclin-dependent kinase 4\/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair-related genes","volume":"6","author":"Bruno","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108335_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","article-title":"A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status","volume":"9","author":"Collins","year":"2021","journal-title":"Oncol Ther"},{"issue":"8110","key":"10.1016\/j.esmoop.2026.108335_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41586-026-10197-0","article-title":"Homologous recombination deficiency and hemizygosity drive resistance in breast cancer","volume":"652","author":"Safonov","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.108335_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103013","article-title":"3MO Analysis of germline BRCA1\/2 mutations and uncommon somatic alterations from patients with HR+, HER2\u2212, node-positive, high-risk early breast cancer enrolled in monarchE","volume":"9","author":"Desmedt","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108335_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.annonc.2021.11.018","article-title":"Veliparib monotherapy following carboplatin\/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial","volume":"33","author":"Han","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108335_bib23","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108335_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2026.108335_bib25","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"3","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108335_bib26","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108335_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1151496","article-title":"HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer","volume":"13","author":"Olivera-Salguero","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108335_bib28","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108335_bib29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108335_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2018.04.015","article-title":"Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer","volume":"67","author":"Cejalvo","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.108335_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1009352","article-title":"Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive\/HER2-negative metastatic breast cancer with visceral crisis: a case report","volume":"12","author":"Schettini","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.108335_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104439","article-title":"Identifying germline pathogenic variants in breast cancer using tumor sequencing","volume":"81","author":"Cruellas","year":"2025","journal-title":"Breast"},{"issue":"28","key":"10.1016\/j.esmoop.2026.108335_bib33","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.esmoop.2026.108335_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.406","article-title":"304P ESR1 mutations and outcomes in BRCA1\/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial","volume":"31","author":"Frenel","year":"2020","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2026.108335_bib35","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-24-4221","article-title":"Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+\/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial","volume":"31","author":"Guiu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108335_bib36","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.3390\/cancers12092480","article-title":"CDK4\/6 inhibitors in hormone receptor-positive metastatic breast cancer: current practice and knowledge","volume":"12","author":"de Melo Gagliato","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108335_bib37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.34525","article-title":"Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial","volume":"153","author":"Senkus","year":"2023","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108335_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-023-07165-x","article-title":"Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY","volume":"204","author":"Balmana","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108335_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41523-025-00859-z","article-title":"Real-world effectiveness of PARP inhibitors after CDK4\/6 inhibitor therapy in BRCA-mutated HR-positive\/HER2-negative advanced breast cancer","volume":"11","author":"Zattarin","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108335_bib40","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108335_bib41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-021-00224-w","article-title":"Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants","volume":"7","author":"Lambertini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108335_bib42","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Mavaddat","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108335_bib43","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2013 association analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108335_bib44","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:34:56Z","timestamp":1787848496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022775"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108335","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4\/6 inhibitors plus endocrine therapy in HR-positive\/HER2-negative metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108335"}}